Patents by Inventor Martin G. Pomper

Martin G. Pomper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
    Patent number: 12233137
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 25, 2025
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
    Publication number: 20250057996
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Application
    Filed: August 11, 2023
    Publication date: February 20, 2025
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • Inhibition Of Rip Kinases For Treating Neurodegenerative Disorders
    Publication number: 20240398824
    Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.
    Type: Application
    Filed: June 12, 2024
    Publication date: December 5, 2024
    Inventors: Seulki Lee, Han Seok Ko, Ted M. Dawson, Martin G. Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park
  • Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?)
    Patent number: 12115233
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Grant
    Filed: February 23, 2024
    Date of Patent: October 15, 2024
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • PSMA-based molecular-genetic reporter system
    Patent number: 12104214
    Abstract: Methods, reporter gene constructs, and kits for using prostate-specific membrane antigen (PSMA) as an imaging reporter to image a variety of cells and tissues are provided.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 1, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Mark Castanares, Il Minn, Shawn Lupold
  • IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
    Publication number: 20240293584
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Application
    Filed: February 23, 2024
    Publication date: September 5, 2024
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • PSMA-binding agents and uses thereof
    Patent number: 12070513
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: August 27, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA targeted fluorescent agents for image guided surgery
    Patent number: 12065413
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: August 20, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
    Publication number: 20240150323
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 9, 2024
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY
    Publication number: 20240140971
    Abstract: PSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
    Type: Application
    Filed: June 14, 2023
    Publication date: May 2, 2024
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES RECOGNIZING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
    Publication number: 20240101706
    Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 28, 2024
    Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss
  • Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)
    Patent number: 11938201
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: March 26, 2024
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
    Patent number: 11911488
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 27, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA
    Publication number: 20230414762
    Abstract: A non-radioactive prodrug comprising a PSMA-targeted moiety, a cleavable linker, and an antineoplastic agent capable of selectively killing PSMA-expressing cells and methods of treating a disease or condition associated with PSMA-expressing tumors or cells is disclosed.
    Type: Application
    Filed: November 17, 2021
    Publication date: December 28, 2023
    Inventors: Srikanth Boinapally, IL Minn, Martin G. Pomper
  • Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL
    Patent number: 11851407
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 26, 2023
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
  • IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
    Publication number: 20230364274
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 16, 2023
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • PSMA targeted fluorescent agents for image guided surgery
    Patent number: 11814365
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 14, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
    Patent number: 11813340
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: November 14, 2023
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • PSMA-TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20230348405
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: November 4, 2022
    Publication date: November 2, 2023
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
    Patent number: 11773182
    Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 3, 2023
    Assignees: The Johns Hopkins University, Institute of Biotechnology CAS, V.V.I.
    Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss